This phenomenon also occurs when cholinesterase inhibitors, including DON, neostigmine and galantamine, are used to treat other diseases; for example, with the oral administration of DON to treat mild cognitive impairment (16,17) and the oral or intramuscular injection of neostigmine treatment for myasthenia gravis (28). The gene discussed is BCHE; the disease is myasthenia gravis.